Clinical Competition Candidate

ATROVENT HFA

Respiratory · COPD, bronchospasm (anticholinergic bronchodilator)

ATROVENT HFA carries product patent, low complexity (0/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 42 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

42months

to latest listed patent expiry (January 17, 2030)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (none)

Patent count: 1

Complexity score: 0/5

Clinical competition

Score: 5/5

Active trials linked: 226

Phase 2/3 trials: 97

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: IPRATROPIUM BROMIDE

Applicant (NDA holder): BOEHRINGER INGELHEIM PHARMACEUTICALS INC

Confidence: High

Market context

Therapeutic area: Respiratory

Indication: COPD, bronchospasm (anticholinergic bronchodilator)

U.S. market size (est.)< $100M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.